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Encapsulating  peritoneal  sclerosis:  A review  of 3 cases
Esclerosis  peritoneal  encapsulante:  revisión  de  3  casos
To the Editor,
Encapsulating peritoneal sclerosis (EPS) is an uncommon but
severe complication among patients on peritoneal dialysis
(PD). This report describes three patients from our centre who
were diagnosed of EPS collected during a 20-year period.
Case  1
septa comprising loops, and large gastric and intestinal dilata-
tion were observed in a CT scan (Fig. 1). Surgery was not
considered and the patient was hospitalised several times
because of intestinal occlusion; his general condition became
progressively worse and he died soon after.
Case  3A female patient with Laurence-Moon-Biedl syndrome.
Haemodialysis (HD) was started at the age of 11. She received
A male patient who had focal segmental hyalinosis which was
refractory to steroids, cyclophosphamide, and vincristine. He
started PD in 1990. During the following 11 years he received 3her ﬁrst renal transplant in the following year, which failed
due to thrombosis of the vein graft. Two years later, she was
started on PD because of difﬁculties with vascular access.
The patient developed several peritonitis and severe hyper-
parathyroidism. Her peritoneal transport was medium–high
at baseline. After 12 years of dialysis, this patient had a new
onset of peritonitis, associated with tunnel infection and perit-
oneal ventral hernia in the catheter site. Ultrasounds revealed
sclerosis and peritoneal calciﬁcation with compressed abdom-
inal viscera. The patient received antibiotics, the catheter
was withdrawn, and she was started on HD. She later devel-
oped acute ischaemia in the right lower limb as a result of
femoral–popliteal obstruction. Surgery was not considered
due to the poor patient’s clinical condition, and she died soon
after.
Case  2
A male patient diagnosed of rapidly progressive glomeru-
lonephritis with basal glomerular anti-membrane antibodies
was treated with steroids, cyclophosphamide, and plasma-
pheresis with no positive results. In his 5 years of PD, the
patient developed 10 episodes of peritonitis, 8 of which were
due to Staphylococcus aureus.  The last peritonitis was caused
by Candida albicans; and for this reason, the catheter was with-
drawn and the patient started HD.
Peritoneal transport was originally medium–high, and
ﬁnally became high. Six months later the patient developed
abdominal pain and a mass effect was reﬂected in the supra-
pubic region. Peritoneal thickening, pelvic ﬂuid collection with
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underwent parathyroidectomy due to severe hyperparathy-
roidism.
Peritoneal transport remained medium–high with a ten-
dency to increase. Ultraﬁltration decreased over time and the
need for osmotic solutions was greater. CA-125 was measured
in the peritoneal efﬂuent several times and a gradual decrease
was observed over time. The patient had 12 peritonitis, all of
them caused by Gram positive germs. HD was indicated, but
the patient still tried to avoid it by all means; he ﬁnally started
HD in 2011.
Six months later, he was admitted with pain and abdominal
distension. A CT scan of the abdomen (Fig. 2A) showed gastric
and duodenal dilatation with free loculated ﬂuid and oedema-
tous bowel. A peritoneal biopsy revealed proliferation of small
vessels, inﬂammatory cellularity, and ﬁbrosis (Fig. 2B). After
EPS was diagnosed, treatment with prednisone and tamoxifen
was started. The size of the collection had decreased after six
months, and no loop dilatation was observed. The patient did
not developed more  complications. He is currently receiving
HD and tamoxifen.
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The incidence of EPS in our Nephrology service was 0.47%
lower compared to other case studies where it ranges between
0.7 and 7.3%.1–3 It is an uncommon but severe complication
characterised by a high mortality rate (two of our patients
died). Pathogenesis is unclear, and constant peritoneal inﬂam-
mation associated with glucose and glucose-degradation
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Fig. 1 – CT scan: thickened peritoneum associated with pelvic ﬂuid collection with septa inside and air-ﬂuid levels.
products is thought to enhance peritoneal permeability to cer-
tain substances, including ﬁbrin, thereby promoting ﬁbrosis;
in addition, a second stimulus, such as peritonitis, abdominal
surgery, bioincompatibility of solutions, or long time in PD,4–7
may accelerate progression or ultimately trigger EPS.2 Some of
these have been clearly implicated in the development of EPS
in our patients.
Finally, both the interruption of the washout and the build-
up of proﬁbrotic factors,8 as well as the use of anti-calcineurin
drugs, give rise to increased ﬁbrosis.9
Clinical manifestations of EPS consist of signs and symp-
toms of bowel obstruction.10 X-rays show an image  of “cocoon”
(encased loops due to ﬁbrosis), adhesions, air-ﬂuid levels,
and peritoneal calciﬁcation. Diagnosis is conﬁrmed by his-
tological ﬁndings: mesothelial detachment and thickened
peritoneum with ﬁbrin deposition, inﬂammatory inﬁltrates,
capillary angiogenesis, and calciﬁcation.10
No biochemical markers or X-ray examinations are able
to screen patients at risk of EPS. Low CA-125 and high IL-6
in the peritoneal efﬂuent have been suggested as prognostic
F
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ig. 2 – (A) CT scan: gastric and duodenal dilatation, with abunda
ntestine loops. (B) Peritoneal biopsy; haematoxylin and eosin stnt intra-abdominal loculated ﬂuid, and shift of small
aining, and immunohistochemistry techniques.
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factors.11 Our third patient developed a progressive decrease
during PD.
Prevention is the treatment cornerstone, including
stronger and earlier options, such as the use of biocompatible
solutions and early screening. Immunosuppresants, partic-
ularly corticosteroids and tamoxiphen, are the treatment
of choice for the management of inﬂammation as a result
of their anti-ﬁbrotic effects. In advanced stages, adhesions
and encased loops can be released by surgery, and yet,
even though intestinal obstruction is reverted, peritoneal
impairment is not halted.4
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